Drug-induced long QT and torsade de pointes: recent advances.
Kannankeril PJ, Roden DM.
Curr Opin Cardiol. 2007 Jan;22(1):39-43. doi: 10.1097/HCO.0b013e32801129eb.
Drug-induced prolongation of the QT interval.
Roden DM.
N Engl J Med. 2004 Mar 4;350(10):1013-22. doi: 10.1056/NEJMra032426.
Drug-induced torsade de pointes. Incidence, management and prevention.
Faber TS, Zehender M, Just H.
Drug Saf. 1994 Dec;11(6):463-76. doi: 10.2165/00002018-199411060-00007.
Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
Jackobson G, Carmel NN, Lotan D, Kremer A, Justo D.
Z Gerontol Geriatr. 2018 Jan;51(1):41-47. doi: 10.1007/s00391-016-1155-5. Epub 2016 Nov 22.
Seizure-induced Torsades de pointes:In a canine drug-induced long-QT1 model.
van der Linde H, Kreir M, Teisman A, Gallacher DJ.
J Pharmacol Toxicol Methods. 2021 Sep-Oct;111:107086. doi: 10.1016/j.vascn.2021.107086. Epub 2021 Jun 10.
Assessing predictors of drug-induced torsade de pointes.
Belardinelli L, Antzelevitch C, Vos MA.
Trends Pharmacol Sci. 2003 Dec;24(12):619-25. doi: 10.1016/j.tips.2003.10.002.
Drug-induced long QT syndrome and torsade de pointes.
Morissette P, Hreiche R, Turgeon J.
Can J Cardiol. 2005 Aug;21(10):857-64.
Drug-induced long-QT syndrome and torsade de pointes: an underrated problem?
Rao P, Kowey PR.
Europace. 2014 Jan;16(1):4-5. doi: 10.1093/europace/eut331. Epub 2013 Nov 4.
Drug-induced QT dispersion: does it predict the risk of torsade de pointes?
Shah RR.
J Electrocardiol. 2005 Jan;38(1):10-8. doi: 10.1016/j.jelectrocard.2004.09.001.
Pharmacological treatment of acquired QT prolongation and torsades de pointes.
Thomas SH, Behr ER.
Br J Clin Pharmacol. 2016 Mar;81(3):420-7. doi: 10.1111/bcp.12726. Epub 2015 Oct 26.
